Development of a CD22-specific chimeric antigen receptor (CAR) for the adoptive T cell therapy of leukemia and lymphoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
Heidelberg, Universität Heidelberg, Dissertation, 2017
- Keyword
-
Leukemia
Cellular therapy
- Event
-
Veröffentlichung
- (where)
-
Heidelberg
- (who)
-
Universitätsbibliothek Heidelberg
- (when)
-
2020
- Creator
- Contributor
- DOI
-
10.11588/heidok.00022968
- URN
-
urn:nbn:de:bsz:16-heidok-229686
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:54 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Aichelin, Katharina
- Angel, Peter
- Universitätsbibliothek Heidelberg
Time of origin
- 2020
Other Objects (12)
"CAR-engineered lymphocytes for targeted therapy of leukemia and lymphoma"
Adoptive T-cell Therapy via Chimeric Antigen Receptors (CARs) against Leukemia in Combination with a human Suicide Gene
A novel dual chain-based design of a chimeric antigen receptor (CAR) for adoptive cell therapy and an FcR-specific CAR for improved targeting of chronic lymphocytic Leukemia (CLL)
Chimeric antigen receptor (CAR)-modified T cells targeting FLT3 in acute myeloid leukemia (AML)
Leukemia and non-Hodgkin lymphoma
Optimization of chimeric antigen receptor (CAR) therapy
Chimeric antigen receptor T cells for acute myeloid leukemia
Improvement of Chimeric Antigen Receptor-Specific T Cells for Adoptive T Cell Transfer
GD2-spezifische CAR-NK-Zellen für die adoptive Krebsimmuntherapie
T cell receptor diversity prevents T cell leukemia, lymphoma development
Ibrutinib for improved chimeric antigen receptor T cell production for chronic lymphocytic leukemia patients
Current limitations and perspectives of chimeric antigen receptor-T-cells in acute myeloid leukemia
"CAR-engineered lymphocytes for targeted therapy of leukemia and lymphoma"
Adoptive T-cell Therapy via Chimeric Antigen Receptors (CARs) against Leukemia in Combination with a human Suicide Gene
A novel dual chain-based design of a chimeric antigen receptor (CAR) for adoptive cell therapy and an FcR-specific CAR for improved targeting of chronic lymphocytic Leukemia (CLL)
Chimeric antigen receptor (CAR)-modified T cells targeting FLT3 in acute myeloid leukemia (AML)
Leukemia and non-Hodgkin lymphoma
Optimization of chimeric antigen receptor (CAR) therapy
Chimeric antigen receptor T cells for acute myeloid leukemia
Improvement of Chimeric Antigen Receptor-Specific T Cells for Adoptive T Cell Transfer
GD2-spezifische CAR-NK-Zellen für die adoptive Krebsimmuntherapie
T cell receptor diversity prevents T cell leukemia, lymphoma development
Ibrutinib for improved chimeric antigen receptor T cell production for chronic lymphocytic leukemia patients
Current limitations and perspectives of chimeric antigen receptor-T-cells in acute myeloid leukemia
"CAR-engineered lymphocytes for targeted therapy of leukemia and lymphoma"
Adoptive T-cell Therapy via Chimeric Antigen Receptors (CARs) against Leukemia in Combination with a human Suicide Gene
A novel dual chain-based design of a chimeric antigen receptor (CAR) for adoptive cell therapy and an FcR-specific CAR for improved targeting of chronic lymphocytic Leukemia (CLL)
Chimeric antigen receptor (CAR)-modified T cells targeting FLT3 in acute myeloid leukemia (AML)
Leukemia and non-Hodgkin lymphoma
Optimization of chimeric antigen receptor (CAR) therapy
Chimeric antigen receptor T cells for acute myeloid leukemia
Improvement of Chimeric Antigen Receptor-Specific T Cells for Adoptive T Cell Transfer
GD2-spezifische CAR-NK-Zellen für die adoptive Krebsimmuntherapie
T cell receptor diversity prevents T cell leukemia, lymphoma development
Ibrutinib for improved chimeric antigen receptor T cell production for chronic lymphocytic leukemia patients